Eligo Bioscience

Eligo Bioscience is a leading gene-editing company focused on developing precision medicines to address diseases driven by the expression of bacterial genes from the microbiome. The company leverages its proprietary GEM (Gene Editing of the Microbiome) platform to engineer phage particles, known as Eligobiotics, which can deliver therapeutic DNA payloads to target specific bacterial populations within the microbiome. This technology enables Eligo to precisely modify the composition and function of the microbiome in vivo, offering a novel approach to treating a wide range of diseases, including inflammatory diseases, oncology, and infectious diseases.

Eligo's innovative approach has garnered significant attention and support from the scientific and investment communities. The company has been recognized as a Technology Pioneer by the World Economic Forum and has secured funding from prominent investors such as Sanofi Ventures, Khosla Ventures, and Seventure Partners. Eligo is currently advancing its pipeline of drug candidates through preclinical and clinical development, with the aim of bringing its first products to market in the coming years.

Eligo Bioscience offers a flexible work policy, allowing employees to work remotely up to two days per week if compatible with their responsibilities.

Eligo Bioscience provides its employees with a comprehensive benefits package that includes competitive salary and equity packages, 8€ Tickets Restaurant per working day, 100% coverage of top-tier health insurance (Alan) for both employees and their children, 100% reimbursement of Navigo transportation card costs or 400€/year for alternative transport support, 100% coverage of weekly French or English classes, 100% coverage of gym memberships, 9-11 days of RTT per year, and a flexible remote work policy allowing for two days per week if compatible with responsibilities.

Eligo Bioscience is a pioneering gene-editing company focused on developing precision medicines to address diseases driven by the expression of bacterial genes from the microbiome. They are committed to advancing a highly differentiated pipeline of therapies for unmet medical needs in immunoinflammation, oncology, and infectious diseases, through precise genetic modification within the human microbiome.

Eligo Bioscience cultivates a fast-paced, international, and collaborative work environment where creativity and passion are valued. They prioritize innovation, with a focus on applying cutting-edge technologies to solve real-world problems. The company embraces diversity and inclusion, offering comprehensive benefits and perks that support employee well-being, including competitive salaries and equity packages, health insurance, transportation reimbursement, and even gym memberships. The vibrant Parisian location provides employees with access to a range of cultural experiences and a unique company culture.

Eligo Bioscience promotes a diverse and inclusive workplace, boasting a team representing 10 nationalities with a 1:1 gender ratio. The company explicitly states that it is an LGBTQ-friendly business, ensuring that all employees feel comfortable and respected regardless of their background or identity. Eligo's dedication to diversity is evident in its commitment to building a collaborative and supportive environment where everyone feels valued and has the opportunity to contribute to their full potential.